Search results for "Oral contraceptive"

showing 7 items of 7 documents

Giant hepatocellular adenoma as cause of severe abdominal pain: a case report

2007

Abstract The authors describe the case of a large hepatocellular adenoma diagnosed in a 30-year old woman who came to us complaining of acute pain in the upper abdominal quadrants. The patient had been taking an oral contraceptive pill for the last ten years. We present the clinical features, the diagnostic work-up and the treatment prescribed.

Abdominal painPathologyoral contraceptive agent EMTREE medical terms: abdominal painanamnesilcsh:Medicinecomputer assisted tomographyaspartate aminotransferaseSurgical oncologynuclear magnetic resonance imagingMedicine(all)oral contraceptionadultarticleGeneral MedicineAbdominal quadrantsfemalepriority journalhistopathologycontrast enhancementdisease severitymedicine.symptomEMTREE drug terms: alanine aminotransferasemedicine.medical_specialtyOral contraceptive pillcontrast mediummedicinediffusion weighted imagingcase reportfollow uphumanAcute painliver biopsydrug useliver lobectomybusiness.industryGeneral surgeryPublic healthlcsh:RechographyHepatocellular adenomaliver angiographymedicine.diseasetumor bleedinghuman tissueclinical featurenausea and vomitingbusinessaspartate aminotransferase blood levelliver adenomaalanine aminotransferase blood level
researchProduct

Vesico-uterine fistula treated by amenorrhoea induced with contraceptive steroids. Two case reports.

1980

2 case reports of women with vesico-uterine fistulae who were successfully treated by inducing amenorrhea by the continuous administration of an estrogen-progestogen compound for 6 months are presented. Ortho-Novum 1/50 was used. The amenorrheic condition induced by continuous ingestion of an oral contraceptive agent allowed the fistula time to heal since fistulae rarely close spontaneously because of fluids flowing fhrough them inhibiting the healing process. This method of management should be tried before surgery the generally recommended treatment.

AdultUterine Diseasesmedicine.medical_specialtyFistulabusiness.industryUrinary Bladder FistulaResearch methodologyFistulaObstetrics and GynecologyUterine Fistulamedicine.diseaseOral contraceptive agentSurgeryContraceptives Oral CombinedFamily planningmedicineHumansAmenorrheaFemalemedicine.symptombusinessAmenorrheaContraceptives OralBritish journal of obstetrics and gynaecology
researchProduct

The impact of using the combined oral contraceptive pill for cycle scheduling on gene expression related to endometrial receptivity.

2014

STUDY QUESTION: Does the combined oral contraceptive pill (COCP) change endometrial gene expression when used for cycle programming? SUMMARY ANSWER: COCP used for scheduling purposes does not have a significant impact on endometrial gene expression related to endometrial receptivity. WHAT IS KNOWN ALREADY: Controversy exists around COCP pretreatment for IVF cycle programming as some authors claim that it might be detrimental to the live birth rate. Microarray technology applied to the study of tissue gene expression has previously revealed the behavior of genes related to endometrial receptivity under different conditions. STUDY DESIGN SIZE AND DURATION: Proof-of-concept study of 10 young h…

Adultmedicine.medical_specialtyAdolescentmedicine.medical_treatmentPopulationUterusGene ExpressionEndometriumEndometriumYoung AdultOvulation InductionmedicineHumansEmbryo ImplantationeducationMenstrual CycleGynecologyeducation.field_of_studyPregnancymedicine.diagnostic_testGenitourinary systembusiness.industryRehabilitationObstetrics and Gynecologymedicine.diseaseContraceptives Oral Combinedmedicine.anatomical_structureReproductive MedicineFemaleCombined oral contraceptive pillLive birthbusinessEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment

2008

The discovery of the Janus kinase 2 Val617Phe mutation has brought new insights into the development of myeloproliferative disorders; however, the pathogenesis of essential thrombocythemia and its related thrombotic complications has not been completely understood. Although the Janus kinase 2 Val617Phe mutation confirms the initially suspected clonal character of the disease, factors influencing clonal transformation and expansion in the bone marrow have not been fully detected. Furthermore, patients affected by essential thrombocythemia who are carriers of the Janus kinase 2 Val617Phe mutation show a higher incidence of venous thromboembolism both before, and at the time of diagnosis, comp…

Adultmedicine.medical_specialtyMutation MissenseOral contraceptiveEssential thrombocythemiaGastroenterologyContraceptives Oral HormonalPathogenesisMesenteric VeinsPortal thrombosisMyeloproliferative DisordersInternal medicinemedicineHumansPlateletSplanchnic CirculationJanus kinase 2Janus kinase 2biologyessential thrombocythemia Janus kinase 2 oral contraceptives portal thrombosisKinaseEssential thrombocythemiaVascular diseasebusiness.industryThrombosisHematologyGeneral Medicinemedicine.diseaseThrombocytopeniaThrombosisEndocrinologybiology.proteinFemalebusiness
researchProduct

Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pill pretreatment.

2007

Objective To evaluate and compare the risk of early pregnancy loss in patients stimulated with GnRH antagonist protocols according to oral contraceptive pill (OCP) pretreatment. Design Retrospective case–control study. Setting Instituto Valenciano de Infertilidad. University of Valencia. Spain. Patient(s) One thousand five hundred thirty-nine patients, aged Intervention(s) Reproductive outcome was compared based on the application (or not) of OCP pretreatment: 944 women were included in the OCP group and 595 in the non-OCP group. The Student's t test was used for statistics. Main Outcome Measure(s) Pregnancy, biochemical pregnancy, ectopic pregnancy, early clinical pregnancy loss, early pre…

Adultmedicine.medical_specialtyOral contraceptive pillPregnancy Ratemedicine.drug_classEarly Pregnancy LossGonadotropin-releasing hormone antagonistMiscarriageGonadotropin-Releasing HormonePregnancymedicineHumansRetrospective StudiesGynecologyPregnancyEctopic pregnancybusiness.industryObstetrics and Gynecologymedicine.diseasePregnancy rateReproductive MedicinePillCase-Control StudiesEmbryo LossFemalebusinessContraceptives OralFertility and sterility
researchProduct

Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial

2013

Abstract Background Both oral contraceptive pills (OCPs) and estradiol (E2) valerate have been used to schedule gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles and, consequently, laboratory activities. However, there are no studies comparing treatment outcomes directly between these two pretreatment methods. This randomized controlled trial was aimed at finding differences in ongoing pregnancy rates between GnRH antagonist IVF cycles scheduled with OCPs or E2 valerate. Methods Between January and May 2012, one hundred consecutive patients (nonobese, regularly cycling women 18–38 years with normal day 3 hormone levels and <3 previous IVF/ICSI attempts)…

Adultmedicine.medical_specialtyPregnancy Ratemedia_common.quotation_subjectPopulationPhysiologyFertilization in VitroCycle schedulingReproductive technologyGonadotropin-releasing hormoneValerateContraceptives Oral Hormonallaw.inventionGonadotropin-Releasing HormoneEndocrinologyRandomized controlled trialPregnancylawInternal medicineGnRH antagonistHumansMedicineeducationMenstrual CycleMenstrual cyclemedia_commonchemistry.chemical_classificationeducation.field_of_studyEstradiolOral contraceptivesbusiness.industryResearchEstradiol valerateEstrogen pretreatmentObstetrics and GynecologyPregnancy rateEndocrinologychemistryReproductive MedicineIVFFemalebusinessmedicine.drugDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?

2013

""The primary aim of the study was to analyze the endometrioma recurrence rate in patients who underwent laparoscopic excision followed by postoperative long-term regimen of oral contraceptives (OCs).. . MATERIALS AND METHODS: 168 patients who underwent a conservative laparoscopic surgery for endometrioma, during the period between September 2009 and August 2010 in three university hospitals were studied. A long-term OCs therapy was offered to all women following surgery. Patients were randomly divided into three groups according to different progestins used (desogestrel, gestodene, dienogest). Women who refused a postoperative hormonal therapy served as control. Follow-up visits and transv…

minimally invasive gynecologic surgeryAdultmedicine.medical_specialtyEndometriosis endometrioma recurrencee oral contraceptives minimally invasive gynecologic surgery progestins dienogest.AdolescentNorpregnenesendometrioma recurrenceeEndometriosisEndometriosisKaplan-Meier EstimateDrug Administration Schedulelaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawSecondary PreventionHumansNandroloneMedicineIn patientOvarian DiseasesYoung adultLaparoscopyoral contraceptivesDesogestrelmedicine.diagnostic_testbusiness.industryObstetricsObstetrics and GynecologyEndometriosis Endometrioma recurrence Oral contraceptives Minimally invasive gynaecologic surgery Progestins DienogestGeneral MedicineLaparoscopic excisionmedicine.diseaseCombined Modality TherapySurgeryRegimenTreatment OutcomeDienogestchemistryprogestinsdienogestFemaleLaparoscopybusinessContraceptives OralFollow-Up Studies
researchProduct